Spinal Cord Stimulation News and Research

RSS

Nevro to initiate Senza HF-SCS System study for chronic pain

Nevro Corp., a medical device company focused on achieving improved pain relief for patients suffering from debilitating chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for initiation of its SENZA-RCT study, a U.S. prospective, randomized, controlled pivotal clinical trial evaluating the safety and efficacy of Nevro's high-frequency spinal cord stimulation system for the treatment of chronic pain.

24 May 2012

Bioness commences StimRouter Neuromodulation System study for chronic peripheral nerve pain

Bioness Inc. today announced the initiation of a study to evaluate the safety and effectiveness of the company's StimRouter Neuromodulation System for those suffering from chronic peripheral nerve pain. This prospective, multi-center, randomized, double-blinded, partial crossover study will enroll 126 patients at up to 10 study sites throughout the United States.

9 Apr 2012

FDA clears additional indications for Anulex’s fiXate Tissue Band product

Anulex Technologies, Inc., a privately held medical device manufacturer, announced today that the U.S. Food and Drug Administration (FDA) has cleared additional indications for use of its fiXate Tissue Band product.

5 Apr 2012

Peripheral nerve stimulation may help manage neuropathic pain in injured soldiers

An peripheral nerve stimulation technique may be a valuable new approach for relief of severe neuropathic (nerve-related) pain in injured soldiers, reports an article in the March issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

22 Mar 2012

New approaches may increase effectiveness of SCS for severe back pain

New approaches to electrical stimulation—using an implanted device with three columns of electrodes—may increase the effectiveness of spinal cord stimulation (SCS) for severe back pain, suggests a study in the March issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

28 Feb 2012

HMS, EPFL to collaborate on 6 pioneering neuroengineering projects

Two of the world's leading universities are joining forces to combine neuroscience and engineering in order to alleviate human suffering caused by such neurological disabilities as paralysis and deafness. Scientists, engineers, and clinicians at Harvard Medical School (HMS) and Ecole Polytechnique F-d-rale de Lausanne (EPFL) will collaborate on six pioneering neuroengineering projects made possible thanks to a $3.6 million grant from the Bertarelli Foundation.

24 Oct 2011

Micro-electrical stimulators for spinal cord injuries

A new wireless device to help victims of spinal cord injury is receiving attention in the research community. Mesut Sahin, PhD, associate professor, in the department of biomedical engineering at NJIT, recently has published and presented news of his findings to develop micro-electrical stimulators for individuals with spinal cord injuries.

18 Oct 2011

FDA clears Anulex's fiXate Tissue Band System to treat chronic trunk/limb pain

Anulex Technologies, Inc., a privately held medical device manufacturer, has announced the U.S. Food and Drug Administration (FDA) clearance to market the fiXate Tissue Band product, designed to secure Spinal Cord Stimulation (SCS) lead anchors to the fascia or interspinous/supraspinous ligament in patients with chronic, intractable pain of the trunk and/or limbs.

21 Sep 2011

Boston Scientific introduces NLI online resource center for healthcare providers

Boston Scientific Corporation has launched its Neuromodulation Learning Institute (NLI), a clinical education program and online resource center for healthcare providers to enhance their knowledge and awareness of spinal cord stimulation (SCS) technology, procedures and techniques.

11 Aug 2011

FDA clears St. Jude Medical's Epiducer lead delivery system for neurostimulation

St. Jude Medical, Inc., a global medical device company, today announced the U.S. Food and Drug Administration (FDA) clearance and limited market release of the Epiducer lead delivery system for neurostimulation therapy.

13 Jul 2011

Nerve stimulation device approved for pain

The Medtronic Inc. has won the CE Mark approval for a peripheral nerve stimulation device for treating chronic back pain. This medical device maker from Minneapolis, Minn. said the implantable device will fit into its neurostimulation business, which operates out of the company's restorative therapies division. That unit was responsible for about $5.42 billion in sales during the nine-month period ended Jan. 28.

From Medtronic 24 May 2011

NYU Langone researchers present recent findings at The Heart Rhythm Society 32nd annual sessions

Cardiologists from the Cardiac & Vascular Institute at NYU Langone Medical Center presented new research at The Heart Rhythm Society's 32nd Annual Scientific Sessions, May 4 -7 in San Francisco, California.

9 May 2011

Patients with low back pain can benefit from new spinal neuromodulation device

Results from an ongoing prospective study report that a novel spinal neuromodulation device changes the paradigm for patients suffering with low back pain who have not found relief through conventional spinal cord stimulation.

25 Mar 2011

FDA approves Boston Scientific's Clik Anchor for Precision Plus Spinal Cord Stimulator System

Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Clik™ Anchor for its Precision Plus™ Spinal Cord Stimulator (SCS) System, the world's first rechargeable SCS device for chronic pain management. The Clik Anchor features an innovative locking system designed to improve lead anchoring speed and consistency.

25 Mar 2011

Neurostimulation effective for management of chronic pain

St. Jude Medical, Inc., a global medical device company, today announced two-year results in a post-market clinical study evaluating neurostimulation (spinal cord stimulation) for the management of chronic low back pain. Presented at the 14th annual North American Neuromodulation Society (NANS) meeting in Las Vegas, the study found that 70 percent of neurostimulation patients reported overall pain relief of 50 percent or better at their final two-year visit.

4 Dec 2010

FDA clears Multi-Lead Trialing Cable for SCS therapy

Medtronic Inc., the leader in spinal cord stimulation for more than 25 years, today announced U.S. Food and Drug Administration (FDA) clearance and the global launch of the Multi-Lead Trialing Cable for use in the patient screening test for Medtronic spinal cord stimulation (SCS) therapy.

19 Nov 2010

Physicians suggest tips to overcome acute pain

The truth is not all pain is created equal. Acute pain is where it all begins. Lasting for several months, acute pain is typically treated with rest, time and medication. For many, that is enough. But if the pain persists, it converts to chronic pain, and new methods must be explored.

29 Oct 2010

St. Jude Medical receives Japanese approval for Eon Mini spinal cord stimulation system

St. Jude Medical, Inc., a global medical device company, today announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) of the Eon Mini™ spinal cord stimulation (SCS) system. The world's smallest, longest-lasting rechargeable neurostimulator, the Eon Mini device is the first rechargeable spinal cord stimulator to be approved for use in Japan.

30 Sep 2010

SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

Afflicting countless people worldwide, chronic pain is a largely misunderstood and under-treated disease that forever alters the lives of more than 50 million Americans each year.

28 Sep 2010

FDA approves two SCS leads for use with Boston Scientific's Precision Plus Spinal Cord Stimulator System

Boston Scientific Corporation today announced U.S. Food and Drug Administration approval of two spinal cord stimulation (SCS) leads for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk and/or limbs. The Linear™ 3-4 and Linear™ 3-6 Percutaneous Leads offer wider contact spacing to expand the lead choices available to physicians. The Company plans to launch the products immediately in the U.S.; they were launched in Europe and other international markets earlier.

30 Jul 2010